Amgen Shares Rise on Positive Trial Results for Dazodalibep in Sjogren's Disease
Amgen Inc (NASDAQ: AMGN) shares rose modestly after the company announced positive results from its Phase 3 OASIZ 301 trial evaluating dazodalibep for adults with Sjogren's disease. The trial met its primary endpoint, showing significant improvements sustained through 48 weeks.
The company's dividend yield stands at 2.52%, supported by a payout ratio of 44% and a 3-year annualized increase of 7.1%. GuruFocus classifies AMGN as fairly valued with a GF Value™ of $367.41 compared to the current market price of $393.16.
The stock's strong profitability and growth metrics are reflected in its GF Score™ of 86/100, but financial strength concerns persist, including a relatively high debt-to-equity ratio and modest momentum scores. Institutional guru ownership remains strong, with 12 premium gurus holding AMGN shares, although recent activity shows a net trimming trend.